PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26692822-12 2015 Meanwhile, As2O3 antagonized increase of HIF-1alpha protein induced by hypoxia, and it also suppresses the increase in expression levels of P-gp, MRP1, and LRP mRNA and proteins. Arsenic Trioxide 11-16 ATP binding cassette subfamily B member 1 Homo sapiens 140-144 27840903-0 2016 Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line. Arsenic Trioxide 12-28 ATP binding cassette subfamily B member 1 Homo sapiens 66-80 27840903-1 2016 This study investigated arsenic trioxide (As2O3), cisplatin (DDP) and etoposide (Vp16) on the anticancer effects and P-glycoprotein (P-gp) expression in neuroblastoma (NB) SK-N-SH cells. Arsenic Trioxide 24-40 ATP binding cassette subfamily B member 1 Homo sapiens 117-131 27840903-1 2016 This study investigated arsenic trioxide (As2O3), cisplatin (DDP) and etoposide (Vp16) on the anticancer effects and P-glycoprotein (P-gp) expression in neuroblastoma (NB) SK-N-SH cells. Arsenic Trioxide 42-47 ATP binding cassette subfamily B member 1 Homo sapiens 117-131 27840903-9 2016 In vitro examination revealed that following pretreatment of SK-N-SH cells with As2O3, the expression of P-gp was not increased. Arsenic Trioxide 80-85 ATP binding cassette subfamily B member 1 Homo sapiens 105-109 27840903-10 2016 The expression of P-gp downregulation were noted following the group treated by As2O3 at 2 and 3 microM. Arsenic Trioxide 80-85 ATP binding cassette subfamily B member 1 Homo sapiens 18-22 27840903-11 2016 Exposed to As2O3 at 3 microM for 72 h, SK-N-SH cells exhibited lower expression of P-gp than 2 microM As2O3 for 72 h. In contrast, the expression of P-gp was upregulated by DDP and VP16. Arsenic Trioxide 11-16 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 27840903-11 2016 Exposed to As2O3 at 3 microM for 72 h, SK-N-SH cells exhibited lower expression of P-gp than 2 microM As2O3 for 72 h. In contrast, the expression of P-gp was upregulated by DDP and VP16. Arsenic Trioxide 11-16 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 27840903-11 2016 Exposed to As2O3 at 3 microM for 72 h, SK-N-SH cells exhibited lower expression of P-gp than 2 microM As2O3 for 72 h. In contrast, the expression of P-gp was upregulated by DDP and VP16. Arsenic Trioxide 102-107 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 27840903-13 2016 In particular, ours findings showed that low dose of As2O3 markedly reduced the P-gp expression and increased apoptotic cell death in human NB cell line. Arsenic Trioxide 53-58 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 29274627-4 2018 In this study, using human lung adenocarcinoma A549 cells as a cell culture model, we demonstrated that an adenosine triphosphate binding cassette (ABC) transporter, ABCG2, was significantly increased by As2O3 treatment, while other ABC transporters, ABCB1 and ABCC1 showed no remarkable change in the response to As2O3. Arsenic Trioxide 204-209 ATP binding cassette subfamily B member 1 Homo sapiens 251-256 25435954-6 2015 MDR1 expression was downregulated in certain patients following treatment with AS2O3. Arsenic Trioxide 79-84 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 26459009-0 2015 Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic trioxide-induced reduction in drug resistance towards doxorubicin in gastric cancer cell lines. Arsenic Trioxide 60-76 ATP binding cassette subfamily B member 1 Homo sapiens 18-22 26459009-2 2015 Arsenic trioxide (As2O3) has been reported to reduce MDR in various types of cancer, but the mechanisms involving Ras and p-glycoprotein (P-gp) remain to be fully elucidated. Arsenic Trioxide 0-16 ATP binding cassette subfamily B member 1 Homo sapiens 122-136 26459009-2 2015 Arsenic trioxide (As2O3) has been reported to reduce MDR in various types of cancer, but the mechanisms involving Ras and p-glycoprotein (P-gp) remain to be fully elucidated. Arsenic Trioxide 0-16 ATP binding cassette subfamily B member 1 Homo sapiens 138-142 26459009-9 2015 As2O3 treatment decreased the levels of P-gp in a time- and dose-dependent manner (P<0.01). Arsenic Trioxide 0-5 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 25435954-7 2015 In the present study, the overexpression of P-gp was the primary cause of drug resistance in the AML patients, and MDR1 expression was downregulated by As2O3 in primary leukemia and drug-resistant cells. Arsenic Trioxide 152-157 ATP binding cassette subfamily B member 1 Homo sapiens 44-48 25435954-7 2015 In the present study, the overexpression of P-gp was the primary cause of drug resistance in the AML patients, and MDR1 expression was downregulated by As2O3 in primary leukemia and drug-resistant cells. Arsenic Trioxide 152-157 ATP binding cassette subfamily B member 1 Homo sapiens 115-119 18072624-1 2007 OBJECTIVE: To investigate the apoptosis-induction, P-glycoprotein (P-gp) and mdr1 mRNA inhibition effects of arsenic trioxide (As2O3) and buthionine sulfoximine (BSO) on multidrug-resistant cell line K562/ADM cells, and to determine the relationship between intracellular GSH content and arsenic effect. Arsenic Trioxide 109-125 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 24337533-0 2014 Investigation of the mechanism involved in the As2O3-regulated decrease in MDR1 expression in leukemia cells. Arsenic Trioxide 47-52 ATP binding cassette subfamily B member 1 Homo sapiens 75-79 24337533-1 2014 Arsenic trioxide (As2O3) inhibits the expression of P-glycoprotein (P-gp) in leukemia cells; however, the mechanism behind this inhibition is unclear. Arsenic Trioxide 0-16 ATP binding cassette subfamily B member 1 Homo sapiens 52-66 24337533-1 2014 Arsenic trioxide (As2O3) inhibits the expression of P-glycoprotein (P-gp) in leukemia cells; however, the mechanism behind this inhibition is unclear. Arsenic Trioxide 0-16 ATP binding cassette subfamily B member 1 Homo sapiens 68-72 24337533-1 2014 Arsenic trioxide (As2O3) inhibits the expression of P-glycoprotein (P-gp) in leukemia cells; however, the mechanism behind this inhibition is unclear. Arsenic Trioxide 18-23 ATP binding cassette subfamily B member 1 Homo sapiens 52-66 24337533-1 2014 Arsenic trioxide (As2O3) inhibits the expression of P-glycoprotein (P-gp) in leukemia cells; however, the mechanism behind this inhibition is unclear. Arsenic Trioxide 18-23 ATP binding cassette subfamily B member 1 Homo sapiens 68-72 24337533-2 2014 The present study aimed to explore the effect of As2O3 on the expression and regulation of P-gp in leukemia cells, and elucidate the mechanism of the reversal of drug resistance. Arsenic Trioxide 49-54 ATP binding cassette subfamily B member 1 Homo sapiens 91-95 24337533-6 2014 These findings suggest that As2O3 reverses the P-gp-induced drug resistance of leukemia cells through the NF-kappaB pathway. Arsenic Trioxide 28-33 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 24337533-7 2014 As2O3 may inhibit the activity of phosphorylase to inhibit IkappaB phosphorylation, thereby inhibiting NF-kappaB activity and MDR1 gene expression, leading to reversal of drug resistance. Arsenic Trioxide 0-5 ATP binding cassette subfamily B member 1 Homo sapiens 126-130 22959511-3 2012 Furthermore, arsenic trioxide stimulation led to inhibition of P-glycoprotein and Bcl-2 expression. Arsenic Trioxide 13-29 ATP binding cassette subfamily B member 1 Homo sapiens 63-77 19950589-11 2009 At the same time, As2O3 alone and combination with Tan II A therapy can significantly reduce the MR2 cell Pgp expression (P<0.01). Arsenic Trioxide 18-23 ATP binding cassette subfamily B member 1 Homo sapiens 106-109 19950589-12 2009 CONCLUSIONS: There were apoptosis synergism on MR2 cell induced by Tan II A combined with As2O3, at the same time reduced the expression of Pgp in the cells. Arsenic Trioxide 90-95 ATP binding cassette subfamily B member 1 Homo sapiens 140-143 17997939-0 2007 [Effects of arsenic trioxide on expressions of vascular endothelial growth factor and P-glycoprotein in multidrug resistant leukemia cell line K562/A02]. Arsenic Trioxide 12-28 ATP binding cassette subfamily B member 1 Homo sapiens 86-100 17997939-1 2007 OBJECTIVE: To investigate the effects of arsenic trioxide (ATO) on the expressions of vascular endothelial growth factor (VEGF) and P-glycoprotein (P-gp) in K562/A02 cells and to explore the correlation between VEGF and P-gp. Arsenic Trioxide 41-57 ATP binding cassette subfamily B member 1 Homo sapiens 132-146 17997939-1 2007 OBJECTIVE: To investigate the effects of arsenic trioxide (ATO) on the expressions of vascular endothelial growth factor (VEGF) and P-glycoprotein (P-gp) in K562/A02 cells and to explore the correlation between VEGF and P-gp. Arsenic Trioxide 41-57 ATP binding cassette subfamily B member 1 Homo sapiens 148-152 17997939-1 2007 OBJECTIVE: To investigate the effects of arsenic trioxide (ATO) on the expressions of vascular endothelial growth factor (VEGF) and P-glycoprotein (P-gp) in K562/A02 cells and to explore the correlation between VEGF and P-gp. Arsenic Trioxide 59-62 ATP binding cassette subfamily B member 1 Homo sapiens 132-146 17997939-1 2007 OBJECTIVE: To investigate the effects of arsenic trioxide (ATO) on the expressions of vascular endothelial growth factor (VEGF) and P-glycoprotein (P-gp) in K562/A02 cells and to explore the correlation between VEGF and P-gp. Arsenic Trioxide 59-62 ATP binding cassette subfamily B member 1 Homo sapiens 148-152 17997939-5 2007 3.2 micromol/L ATO could remarkably reduce the expression of P-gp in K562/A02 cells after 48- and 72-hour incubation with ATO (P<0.05). Arsenic Trioxide 15-18 ATP binding cassette subfamily B member 1 Homo sapiens 61-65 17997939-5 2007 3.2 micromol/L ATO could remarkably reduce the expression of P-gp in K562/A02 cells after 48- and 72-hour incubation with ATO (P<0.05). Arsenic Trioxide 122-125 ATP binding cassette subfamily B member 1 Homo sapiens 61-65 17997939-6 2007 CONCLUSIONS: The down-regulation of P-gp and VEGF after being exposed to ATO probably contributes to the reversion of multidrug resistance in K562/A02 cells. Arsenic Trioxide 73-76 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 18072624-1 2007 OBJECTIVE: To investigate the apoptosis-induction, P-glycoprotein (P-gp) and mdr1 mRNA inhibition effects of arsenic trioxide (As2O3) and buthionine sulfoximine (BSO) on multidrug-resistant cell line K562/ADM cells, and to determine the relationship between intracellular GSH content and arsenic effect. Arsenic Trioxide 109-125 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 18072624-1 2007 OBJECTIVE: To investigate the apoptosis-induction, P-glycoprotein (P-gp) and mdr1 mRNA inhibition effects of arsenic trioxide (As2O3) and buthionine sulfoximine (BSO) on multidrug-resistant cell line K562/ADM cells, and to determine the relationship between intracellular GSH content and arsenic effect. Arsenic Trioxide 127-132 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 15634520-5 2004 As2O3 at concentrations ranging from 0.5 approximately 2.0 micromol/L could significantly decrease the expression of Pgp and MRP, but not that of LRP. Arsenic Trioxide 0-5 ATP binding cassette subfamily B member 1 Homo sapiens 117-120 15982806-2 2006 In the present study, we examined the effect of As2O3 on multidrug resistant human hepatocellular carcinoma (R-HepG2) cells which are characterized with overexpression of mdr1 gene and P-glycoprotein. Arsenic Trioxide 48-53 ATP binding cassette subfamily B member 1 Homo sapiens 171-175 15982806-2 2006 In the present study, we examined the effect of As2O3 on multidrug resistant human hepatocellular carcinoma (R-HepG2) cells which are characterized with overexpression of mdr1 gene and P-glycoprotein. Arsenic Trioxide 48-53 ATP binding cassette subfamily B member 1 Homo sapiens 185-199 15982806-5 2006 To study the effect of arsenic trioxide on P-glycoprotein, Western analysis probing anti-P-glycoprotein antibody was used to monitor the change of its expression. Arsenic Trioxide 23-39 ATP binding cassette subfamily B member 1 Homo sapiens 43-57 15634520-6 2004 The decrease in the expression of Pgp and MRP in MR2 cell line was negatively correlated with the dose and duration of action of As2O3. Arsenic Trioxide 129-134 ATP binding cassette subfamily B member 1 Homo sapiens 34-37 15634520-7 2004 CONCLUSION: Pgp and MRP, but not LRP, may be the sensitive targets of As2O3 to overcome drug-resistance. Arsenic Trioxide 70-75 ATP binding cassette subfamily B member 1 Homo sapiens 12-15 14642128-0 2003 Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene. Arsenic Trioxide 0-16 ATP binding cassette subfamily B member 1 Homo sapiens 26-40 14642128-0 2003 Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene. Arsenic Trioxide 0-16 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 14642128-1 2003 OBJECTIVE: To investigate the effects of arsenic trioxide (As(2)O(3)) on the apoptosis and p-glycoprotein (P-gp) expression of multidrug-resistant human leukemia cells. Arsenic Trioxide 41-57 ATP binding cassette subfamily B member 1 Homo sapiens 91-105 14642128-1 2003 OBJECTIVE: To investigate the effects of arsenic trioxide (As(2)O(3)) on the apoptosis and p-glycoprotein (P-gp) expression of multidrug-resistant human leukemia cells. Arsenic Trioxide 59-68 ATP binding cassette subfamily B member 1 Homo sapiens 91-105 12679007-0 2003 [Arsenic trioxide inhibits P-glycoprotein expression in multidrug-resistant human leukemia K562/ADM cell line that overexpresses mdr-1 gene and enhances their chemotherapeutic sensitivity]. Arsenic Trioxide 1-17 ATP binding cassette subfamily B member 1 Homo sapiens 129-134 12646961-0 2003 P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cells. Arsenic Trioxide 90-106 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 12646961-0 2003 P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cells. Arsenic Trioxide 90-106 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 12679007-1 2003 OBJECTIVE: To investigate the effects of arsenic trioxide (As(2)O(3)) on the apoptosis and P-glyco-protein (P-gp) expression of multidrug-resistant human leukemia K562/ADM cells, and the combined effects of As(2)O(3) with conventional chemotherapeutic agents. Arsenic Trioxide 41-57 ATP binding cassette subfamily B member 1 Homo sapiens 91-106 12679007-1 2003 OBJECTIVE: To investigate the effects of arsenic trioxide (As(2)O(3)) on the apoptosis and P-glyco-protein (P-gp) expression of multidrug-resistant human leukemia K562/ADM cells, and the combined effects of As(2)O(3) with conventional chemotherapeutic agents. Arsenic Trioxide 59-68 ATP binding cassette subfamily B member 1 Homo sapiens 91-106 34383201-8 2021 RESULTS: Compared to normoxic cells, hypoxic HCC cells were more resistant to ATO, with higher IC50 values and less apoptosis, and upregulated HIF-1alpha protein expression, accompanied with the enhancement of P-glycoprotein and VEGF synthesis after ATO treatment. Arsenic Trioxide 78-81 ATP binding cassette subfamily B member 1 Homo sapiens 210-224 12368167-0 2002 Real-time quantification of the multidrug resistance-1 gene expression in relapsed acute promyelocytic leukemia treated with arsenic trioxide. Arsenic Trioxide 125-141 ATP binding cassette subfamily B member 1 Homo sapiens 32-54 34383201-8 2021 RESULTS: Compared to normoxic cells, hypoxic HCC cells were more resistant to ATO, with higher IC50 values and less apoptosis, and upregulated HIF-1alpha protein expression, accompanied with the enhancement of P-glycoprotein and VEGF synthesis after ATO treatment. Arsenic Trioxide 250-253 ATP binding cassette subfamily B member 1 Homo sapiens 210-224 34383201-10 2021 HIF-1alpha inhibition attenuated ATO resistance and angiogenesis and promoted the anticancer effects of ATO both in vitro and in vivo by downregulating therapy-induced P-glycoprotein and VEGF overexpression. Arsenic Trioxide 104-107 ATP binding cassette subfamily B member 1 Homo sapiens 168-182 31746397-10 2020 In contrast, MDR1 mRNA expression was specifically induced by ATO in the A673 and TC-71 cells, reinforcing the expression differences between MSC and the ES cell lines. Arsenic Trioxide 62-65 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 31302132-8 2019 The MRP1 modulator in combination with BSO also strongly sensitized cancer cells to MRP1-substrate chemotherapeutic agents, particularly arsenic trioxide, and was more effective than either the MRP1 modulator or BSO alone. Arsenic Trioxide 137-153 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 31302132-8 2019 The MRP1 modulator in combination with BSO also strongly sensitized cancer cells to MRP1-substrate chemotherapeutic agents, particularly arsenic trioxide, and was more effective than either the MRP1 modulator or BSO alone. Arsenic Trioxide 137-153 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 31302132-8 2019 The MRP1 modulator in combination with BSO also strongly sensitized cancer cells to MRP1-substrate chemotherapeutic agents, particularly arsenic trioxide, and was more effective than either the MRP1 modulator or BSO alone. Arsenic Trioxide 137-153 ATP binding cassette subfamily B member 1 Homo sapiens 84-88